Zevra Therapeutics, Inc. ((ZVRA)) has held its Q3 earnings call. Read on for the main highlights of the call.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The recent earnings call of Zevra Therapeutics, Inc. painted a picture of strong performance and strategic advancements, particularly highlighting the success of MIPLYFFA. Despite facing challenges with OLPRUVA and slow enrollment in the DiSCOVER trial, the company maintains a robust financial position, which supports its future strategic goals.
Strong Performance of MIPLYFFA
MIPLYFFA has been a significant contributor to Zevra’s financial success, generating $22.4 million of the total $26.1 million net revenue in the third quarter. The company received 8 new prescription enrollment forms during this period, bringing the total to 137 since its commercial launch a year ago.
European Market Expansion
Zevra is making strides in expanding MIPLYFFA’s reach by filing a Marketing Authorization Application with the European Medicines Agency. This application, now under review, could open doors to a broader patient base in Europe, where approximately 1,100 individuals are affected by Niemann-Pick disease type C.
Patent and Market Access Progress
The company has fortified its patent position for MIPLYFFA and is seeking a patent term extension in the U.S. Additionally, market access has improved, with covered lives increasing to 66% in the third quarter, showcasing strong development in market penetration.
Robust Financial Position
Zevra concluded the third quarter with a solid financial standing, reporting $230.4 million in cash, cash equivalents, and investments. This marks an increase of $12.7 million from the previous quarter, providing ample resources to pursue strategic priorities.
Challenges with OLPRUVA
Despite efforts to differentiate OLPRUVA in the UCD market, the product has struggled to gain traction. Consequently, Zevra has decided to scale back its sales and marketing initiatives for OLPRUVA.
Slow Enrollment in DiSCOVER Trial
The DiSCOVER trial for Celiprolol, aimed at treating Vascular Ehlers-Danlos Syndrome, has faced slow recruitment, with only 5 additional patients enrolled in the third quarter. This brings the total to 44 out of the 150 required for full enrollment.
Forward-Looking Guidance
Looking ahead, Zevra remains optimistic about its growth trajectory. The company continues to focus on expanding MIPLYFFA’s market presence, particularly in Europe, and is committed to advancing its development pipeline. With a strong balance sheet, Zevra is well-positioned to execute its strategic priorities effectively.
In summary, Zevra Therapeutics, Inc.’s earnings call underscored a positive sentiment driven by the strong performance of MIPLYFFA and strategic market expansions. While challenges with OLPRUVA and the DiSCOVER trial were acknowledged, the company’s robust financial health provides a solid foundation for future growth and strategic execution.